Novartis CEO Addresses Investor Concerns Over Patent Expirations with Pipeline Surge
Trendline

Novartis CEO Addresses Investor Concerns Over Patent Expirations with Pipeline Surge

What's Happening? Novartis, a pharmaceutical company, is facing investor concerns regarding significant patent expirations for key commercial assets in the coming years. In response, Novartis CEO Vas Narasimhan has highlighted the company's robust drug pipeline, projecting more than 35 readouts that
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.